ID   NK-92
AC   CVCL_2142
SY   NK92; Natural Killer-92; NK-92.05; Neukoplast; aNK
DR   BTO; BTO:0003287
DR   CLO; CLO_0008177
DR   AddexBio; C0003026/NA
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-2407
DR   BCRC; 60414
DR   BioSample; SAMN03471836
DR   CCRID; 4201HUM-CCTCC00052
DR   Cell_Model_Passport; SIDM01143
DR   Cosmic; 1534874
DR   Cosmic; 1542071
DR   Cosmic; 2025326
DR   Cosmic; 2390215
DR   Cosmic; 2785204
DR   DSMZ; ACC-488
DR   GEO; GSM472001
DR   IPD-IMGT/HLA; 13674
DR   Lonza; 1093
DR   Wikidata; Q17149636
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8152260;
RX   PubMed=9118301;
RX   PubMed=9573023;
RX   PubMed=10365666;
RX   PubMed=10803505;
RX   PubMed=11454312;
RX   PubMed=12850795;
RX   PubMed=18424763;
RX   PubMed=19194464;
RX   PubMed=20454443;
RX   PubMed=21052088;
RX   PubMed=21570725;
RX   PubMed=25586472;
RX   PubMed=26559813;
RX   PubMed=30054012;
RX   PubMed=31126350;
RX   PubMed=31160637;
RX   PubMed=34349345;
CC   Group: Patented cell line.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6670.
CC   Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections.
CC   Characteristics: IL2 dependent.
CC   Characteristics: Does not express FCGR3A/CD16.
CC   Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Transcriptome analysis.
CC   Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing.
CC   Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.
CC   Discontinued: AddexBio; C0003026; true.
CC   Discontinued: BCRC; 60414; true.
CC   Derived from sampling site: Peripheral blood. Cell type=Natural killer cell.
ST   Source(s): ATCC; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 11,12
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16,18 (DSMZ)
ST   vWA: 18 (ATCC)
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 17-03-22; Version: 27
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
RX   PubMed=8152260;
RA   Gong J.-H., Maki G., Klingemann H.-G.;
RT   "Characterization of a human cell line (NK-92) with phenotypical and
RT   functional characteristics of activated natural killer cells.";
RL   Leukemia 8:652-658(1994).
RX   PubMed=9118301;
RA   Klingemann H.-G., Wong E., Maki G.;
RT   "A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from
RT   blood.";
RL   Biol. Blood Marrow Transplant. 2:68-75(1996).
RX   PubMed=9573023; DOI=10.1182/blood.V91.10.3850;
RA   Nagashima S., Mailliard R., Kashii Y., Reichert T.E., Herberman R.B.,
RA   Robbins P., Whiteside T.L.;
RT   "Stable transduction of the interleukin-2 gene into human natural
RT   killer cell lines and their phenotypic and functional characterization
RT   in vitro and in vivo.";
RL   Blood 91:3850-3861(1998).
RX   PubMed=10365666; DOI=10.1089/10430349950018030;
RA   Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T.,
RA   Klingemann H.-G.;
RT   "Characterization of genetically altered, interleukin 2-independent
RT   natural killer cell lines suitable for adoptive cellular
RT   immunotherapy.";
RL   Hum. Gene Ther. 10:1359-1373(1999).
RX   PubMed=10803505; DOI=10.1038/sj.leu.2401778;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   natural killer cell leukemia-lymphoma.";
RL   Leukemia 14:777-782(2000).
RX   PubMed=11454312; DOI=10.1089/152581601750288975;
RA   Maki G., Klingemann H.-G., Martinson J.A., Tam Y.K.;
RT   "Factors regulating the cytotoxic activity of the human natural killer
RT   cell line, NK-92.";
RL   J. Hematother. Stem Cell Res. 10:369-383(2001).
RX   PubMed=12850795; DOI=10.1080/14653240310001523;
RA   Tam Y.K., Martinson J.A., Doligosa K., Klingemann H.-G.;
RT   "Ex vivo expansion of the highly cytotoxic human natural killer-92
RT   cell-line under current good manufacturing practice conditions for
RT   clinical adoptive cellular immunotherapy.";
RL   Cytotherapy 5:259-272(2003).
RX   PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392;
RA   Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S.,
RA   Weiner L.M.;
RT   "Blocking NK cell inhibitory self-recognition promotes
RT   antibody-dependent cellular cytotoxicity in a model of anti-lymphoma
RT   therapy.";
RL   J. Immunol. 180:6392-6401(2008).
RX   PubMed=19194464; DOI=10.1038/leu.2009.3;
RA   Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H.,
RA   Klinkebiel D., Christman J.K., Patel K., Cao K., Shen L., Dybkaer K.,
RA   Tsui I.F.L., Ali H., Shimizu N., Au W.Y., Lam W.L., Chan W.C.;
RT   "Genomic analyses reveal global functional alterations that promote
RT   tumor growth and novel tumor suppressor genes in natural killer-cell
RT   malignancies.";
RL   Leukemia 23:1139-1151(2009).
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767-904767(2010).
RX   PubMed=21052088; DOI=10.1038/leu.2010.255;
RA   Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.Y., Srivastava G.,
RA   Greiner T.C., Kucuk C., Deffenbacher K., Vose J., Smith L., Au W.Y.,
RA   Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H.,
RA   Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.C.;
RT   "Natural killer cell lymphoma shares strikingly similar molecular
RT   features with a group of non-hepatosplenic gammadelta T-cell lymphoma
RT   and is highly sensitive to a novel aurora kinase A inhibitor in
RT   vitro.";
RL   Leukemia 25:348-358(2011).
RX   PubMed=21570725; DOI=10.1016/j.molimm.2011.04.010;
RA   Schnueriger A., Grau R., Sondermann P., Schreitmueller T., Marti S.,
RA   Zocher M.;
RT   "Development of a quantitative, cell-line based assay to measure ADCC
RT   activity mediated by therapeutic antibodies.";
RL   Mol. Immunol. 48:1512-1517(2011).
RX   PubMed=25586472; DOI=10.1038/ncomms7025;
RA   Kucuk C., Jiang B., Hu X.-Z., Zhang W.-Y., Chan J.K.C., Xiao W.-M.,
RA   Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A.,
RA   Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W.-W., Cornish A.,
RA   Gong Q., Yang Q.-P., Sun H., d'Amore F.A., Leppa S., Liu W.-P., Fu K.,
RA   de Leval L., McKeithan T., Chan W.C.;
RT   "Activating mutations of STAT5B and STAT3 in lymphomas derived from
RT   gammadelta-T or NK cells.";
RL   Nat. Commun. 6:6025.1-6025.12(2015).
RX   PubMed=26559813; DOI=10.1007/s00262-015-1761-x;
RA   Suck G., Odendahl M., Nowakowska P., Seidl C., Wels W.S.,
RA   Klingemann H.-G., Tonn T.;
RT   "NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer
RT   cell-based cancer immunotherapy.";
RL   Cancer Immunol. Immunother. 65:485-492(2016).
RX   PubMed=30054012; DOI=10.1016/j.molimm.2018.07.015;
RA   Gunesch J.T., Angelo L.S., Mahapatra S., Deering R.P., Kowalko J.E.,
RA   Sleiman P., Tobias J.W., Monaco-Shawver L., Orange J.S., Mace E.M.;
RT   "Genome-wide analyses and functional profiling of human NK cell
RT   lines.";
RL   Mol. Immunol. 115:64-75(2019).
RX   PubMed=31126350; DOI=10.1186/s40425-019-0612-2;
RA   Yang H.G., Kang M.C., Kim T.Y., Hwang I., Jin H.T., Sung Y.C.,
RA   Eom K.-S., Kim S.W.;
RT   "Discovery of a novel natural killer cell line with distinct
RT   immunostimulatory and proliferative potential as an alternative
RT   platform for cancer immunotherapy.";
RL   J. Immunother. Cancer 7:138.1-138.17(2019).
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
RX   PubMed=34349345; DOI=10.1007/s10616-021-00476-1;
RA   Zhao H., Zhou Z.-L., Li G.-M., Liu G., Lin S.-Y., Chen W., Xiong S.;
RT   "An NK cell line (NK92-41BB) expressing high levels of granzyme is
RT   engineered to express the high affinity chimeric genes CD16/CAR.";
RL   Cytotechnology 73:539-553(2021).